We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

By LabMedica International staff writers
Posted on 06 Mar 2023
Print article
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil differ significantly amongst them, with some experiencing good, long-term responses but others receiving no benefits as their cancers become resistant to each treatment. Now, researchers have discovered that a genetic test, an established part of standard care in the UK and globally to predict patients' responses to other targeted cancer drugs, can also predict whether chemotherapy will work for bowel cancer patients. This discovery could aid in sparing patients from unnecessary toxicity and debilitating side effects by avoiding treatments that will not benefit them.

A team of researchers, including investigators from Imperial College London (London, UK), has discovered that a particular mutation - referred to as KRASG12 - in the KRAS gene is linked to a lower survival rate in treated patients. On the other hand, another mutation was found to be associated with a three-fold increase in survival. The study's results suggest that patients with KRASG12 mutations - constituting nearly 28% of all bowel cancer patients - gain no benefit from trifluridine/tipiracil and should consider partaking in clinical trials rather than enduring unnecessary toxicity. Conversely, patients without KRAS mutations may benefit from trifluridine/tipiracil, while those with a KRASG13 mutation are likely to respond well to treatment.

As part of standard NHS care, patients with advanced bowel cancer are already given gene tests to search for mutations in KRAS and identify those who can benefit from a targeted medicine called cetuximab. Doctors can now use the same test right away to commence treatment with trifluridine/tipiracil based on this evidence. The researchers have asked regulators to quickly incorporate the findings into guidelines which would make it standard to use the test for directing treatment with trifluridine/tipiracil.

“This is the first time we have a genomic marker already used in the clinic that can tell us whether a patient’s cancer will be sensitive or resistant to chemotherapy. We hope doctors will use this data to improve care for patients with advanced bowel cancer without delay,” said Professor Nicola Valeri, Honorary Professor of Gastrointestinal Oncology at Imperial College London and the ICR. “It will be difficult for some patients to find out that this last-line drug will not benefit them, but this test will mean they are able to avoid unnecessary side effects and have a better quality of life with advanced cancer. Fortunately, our findings also reveal a group of patients who see substantial benefits from taking this type of chemotherapy.”

Related Links:
Imperial College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more